10/551755

# JC05 Rec'd PCT/PTO 33 OCT 2005 PATENT APPLICATION

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q90669

Yoshifumi TAKENOBU, et al.

Appln. No.: National Stage Entry of PCT/JP2004/004836

Confirmation No.: Unknown Group Art Unit: Unknown

Filed: October 03, 2005 Examiner: Unknown

For: REMEDY FOR SPINAL CANAL STENOSIS

### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

JC05 Rec'd PCT/PTO 03 OCT 2005

10/551755

INFORMATION DISCLOSURE STATEMENT National Stage Entry of PCT/JP2004/004836

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents, together with an

English-language version (if not already included) of at least that portion of the Communication

indicating the degree of relevance found by the foreign patent office.

Additionally, WO 98/34916 corresponds to US 6,288,119.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

washington office 23373

CUSTOMER NUMBER

Date: October 3, 2005

2

#### JC05 Rec'd PCT/PTO 03 0CT 2005

MODIFIED PTO/SB/08 A & B (06-03)

Substitute for Form 1449 A & B/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known					
Application Number	National Stage Entry of PCT/IP2004/004836				
Confirmation Number	16 6 w 51 755				
Filing Date	October 03, 2005				
First Named Inventor	Yoshifumi TAKENOBU				
Art Unit	Unknown				
Examiner Name	Unknown				
Attorney Docket Number	r Q90669				

U.S. PATENT DOCUMENTS						
Examiner Initials*		Document Number				
	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documen	
		US 6,288,119	Bl	09-11-2001	Shuichi Ohuchida, et al.	
		US				
		US				
		US				
		US				
		US				
-		US				
		US				
		US				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation <sup>6</sup>
		EP	0 860 430	B1	06-12-2002	ONO PHARMACEUTICAL CO., LTD.	
		wo	03/074483	A1	09-12-2003	ONO PHARMACEUTICAL CO., LTD.	Abstract
		WO	98/34916	A1	08-13-1998	ONO PHARMACEUTICAL CO., LTD.	Abstract
				-			
	<del> </del>						
							l

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazin journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where publisher.				
		International Search Report dated July 13, 2004				
		Toshiaki Minami, et al., "Characterization of EP-receptor subtypes involved in allodynia and hyperalgesia induced by intrathecal administration of prostaglandin E <sub>2</sub> to mice", British Journal of Pharmacology, 1004, Vol. 112, Pages 735-740				
		Toshiaki Minami, et al., "Characterization of EP receptor subtypes responsible for prostaglandin E <sub>2</sub> -induced pain responses by use of EP <sub>1</sub> and EP <sub>3</sub> receptor knockout mice", British Journal of Pharmacology, 2001, Vol. 133, pages 438-444				
		Katsuhiko Nakai, et al., "Effects of orally administered OP-1206 α-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model", Prostaglandins Leukotrienes Essential Fatty Acids, Vol. 69, 2003, Pages 269-273				

	T	T
Examiner Signature	 Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.